Drug Database
Back to search

France· FR:66071126

CRYSVITA 20 mg, solution injectable

A burosumab product containing burosumab, registered in France by KYOWA KIRIN HOLDINGS (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC M05BX05

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedCRYSVITA 20 mg, solution injectableATCM05BX05REGISTER NO.FR:66071126PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about burosumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Burosumab is registered in 14 of 19 countries.

Countries holding a registration under ATC M05BX05 (burosumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search burosumab products by name

Burosumab · ATC M05BX05

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
BUROSUMAB
Manufacturer
KYOWA KIRIN HOLDINGS (PAYS-BAS)
Country
France (FR)
ATC code
M05BX05
ATC class
Burosumab
Defined daily dose
2.5 mg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930145227
    1 flacon en verre de 1 mL
    EUR 3.73

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

11 interactions on record for burosumab.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check burosumab against other medicinesHow interaction checks work

Burosumab · interactions on record

11 records

  • 9 severe
  • 2 moderate

Most severe, free to view

  • DihydrotachysterolA11CC02severe
  • CalcitriolA11CC04severe
  • CalcifediolA11CC06severe
  • ParicalcitolA11CC07severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Burosumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All burosumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Crysvita
  • Liechtenstein · Crysvita
  • Norway · Crysvita

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5dcee8a3-2c8e-4736-929a-7c3164e682f4
GET /v1/drugs/5dcee8a3-2c8e-4736-929a-7c3164e682f4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "66071126",
  "date_amm": "2018-02-19",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/17/1262",
  "substance": "BUROSUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about burosumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console